Alkaline ceramidase 3 deficiency aggravates colitis and colitis-associated tumorigenesis in mice by hyperactivating the innate immune system

K Wang1,2,3, R Xu1,2, AJ Snider1,2,4, J Schranda1, Y Li1,2, AB Bialkowska1, M Li5, J Zhou3, YA Hannun1,2, LM Obeid1,2,4, VW Yang1 and C Mao*1,2

Ceramides are the central lipid in the metabolic network of sphingolipids, and are generated through the de novo, catabolic and salvage pathways.1 In the de novo pathway, ceramides are synthesized through multiple steps catalyzed sequentially by serine palmitoyltransferase (SPT), keto-dihydrosphingosine reductase, (dihydro)ceramide synthases (CerSs) and dihydroceramide desaturases. In the catabolic pathways, ceramides are derived from the hydrolysis of sphingomyelins by sphingomyelinases (SMases) or the salvage pathway, ceramides are derived from the salvage pathway through ceramidases encoded by five distinct genes (ASAH1, ASAH2, ACER1, ACER2 and ACER3). These ceramidases vary in pH optimum for catalytic activity, tissue distribution, cellular localization and substrate specificity,2 allowing for regulation of specific ceramides in a cell- or tissue-specific manner.

Recent studies have implicated ceramides in regulating the innate immune response. Sakata et al.3 demonstrated that lipopolysaccharides (LPS), a potent inducer of the innate immune response, increases C16:0-ceramide by activating acid SMase and that inhibition of SMase attenuates LPS-induced production of pro-inflammatory cytokines in THP-1 macrophages. Andreyev et al.4 found that ceramides are increased by Toll-like receptor 4 (TLR4)-specific LPS in RAW 264.7 macrophages. Schilling et al.5 revealed that LPS and palmitic

OPEN

Citation: Cell Death and Disease (2016) 7, e2124; doi:10.1038/cddis.2016.36 © 2016 Macmillan Publishers Limited All rights reserved 2041-4889/16

www.nature.com/cddis

Increasing studies suggest that ceramides differing in acyl chain length and/or degree of unsaturation have distinct roles in mediating biological responses. However, still much remains unclear about regulation and role of distinct ceramide species in the immune response. Here, we demonstrate that alkaline ceramidase 3 (Acer3) mediates the immune response by regulating the levels of C18:1-ceramide in cells of the innate immune system and that Acer3 deficiency aggravates colitis in a murine model by increasing the expression of pro-inflammatory cytokines in myeloid and colonic epithelial cells (CECs). According to the NCBI Gene Expression Omnibus (GEO) database, ACER3 is downregulated in immune cells in response to lipopolysaccharides (LPS), a potent inducer of the innate immune response. Consistent with these data, we demonstrated that LPS downregulated both Acer3 mRNA levels and its enzymatic activity while elevating C18:1-ceramide, a substrate of Acer3, in murine immune cells or CECs. Knocking out Acer3 enhanced the elevation of C18:1-ceramide and the expression of pro-inflammatory cytokines in immune cells and CECs in response to LPS challenge. Similar to Acer3 knockout, treatment with C18:1-ceramide, but not C18:0-ceramide, potentiated LPS-induced expression of pro-inflammatory cytokines in immune cells. In the mouse model of dextran sulfate sodium-induced colitis, Acer3 deficiency augmented colitis-associated elevation of colonic C18:1-ceramide and pro-inflammatory cytokines. Acer3 deficiency aggravated diarrhea, rectal bleeding, weight loss and mortality. Pathological analyses revealed that Acer3 deficiency augmented colonic shortening, immune cell infiltration, colonic epithelial damage and systemic inflammation. Acer3 deficiency also aggravated colonic dysplasia in a mouse model of colitis-associated colorectal cancer. Taken together, these results suggest that Acer3 has an important anti-inflammatory role by suppressing cellular or tissue C18:1-ceramide, a potent pro-inflammatory bioactive lipid and that dysregulation of ACER3 and C18:1-ceramide may contribute to the pathogenesis of inflammatory diseases including cancer.

Cell Death and Disease (2016) 7, e2124; doi:10.1038/cddis.2016.36; published online 3 March 2016

1Department of Medicine, State University of New York at Stony Brook University, Stony Brook, NY, USA; 2Stony Brook Cancer Center, Stony Brook, NY, USA; 3Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China; 4Northport Veterans Affairs Medical Center, Northport, NY, USA and 5Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China

*Corresponding author: C Mao, Department of Medicine, State University of New York at Stony Brook University, Room T15-023, HSC, Stony Brook, NY 11790-8155, USA. Tel: +1 631 4447726; Fax: +1 631 4446313; E-mail: cungui.mao@stonybrook.edu

Abbreviations: Acer3, alkaline ceramidase 3; CECs, colonic epithelial cells; GEO, NCBI Gene Expression Omnibus; LPS, lipopolysaccharides; SPT, palmitoyltransferase; CerSs, (dihydro)ceramide synthases; SMases, sphingomyelinases; SPh, sphingosine; PMs, peritoneal macrophages; UC, ulcerative colitis; IBD, inflammatory bowel disease; DSS, dextran sulfate sodium; CAC, colitis-associated colon cancer; ULCCs, unsaturated-long-chain ceramides; BMCs, blood mononuclear cells; S1P, sphingosine-1-phosphate

Received 22.10.15; revised 13.1.16; accepted 19.1.16; Edited by H-U Simon
acid synergistically increase C_{16}-ceramide in primary mouse peritoneal macrophages (PMs) by activating de novo biosynthesis of ceramides and that inhibiting the C_{16}-ceramide increase attenuates LPS-induced production of TNF-α and IL-1β in PMs. A recent study found that LPS increases ceramides in Raw 264.7 macrophages through nuclear factor kappa B (NF-κB)-dependent upregulation of SPT long chain base subunit 2 Spltc2, a regulator of SPT.\(^6\) These results suggest that ceramides mediate the immune response in part by enhancing the production of pro-inflammatory cytokines in innate immune cells.

Emerging evidence suggests that dysregulation in the innate immune response in inflammatory bowel disease (IBD) contributes to the pathogenesis of the disease.\(^7\) Consistent with the role of ceramides in potentiating the innate immune response, several studies found that ceramides may have a role in the pathogenesis of IBD. Sakata et al.\(^8\) demonstrated that blocking the generation of ceramides with the SMase inhibitor hinders mouse colitis. Fischbeck et al.\(^8\) showed that increasing ceramides in the gut by supplying mice with dietary sphingomyelins, a precursor of ceramides, aggravates mouse colitis. These results suggest that increased levels of ceramides may contribute to the pathogenesis of IBD.

Although the role of ceramides and their generating enzymes in the innate immune response has been well studied, much remains unclear about the role of ceramidasises involved in the catabolism of ceramides in this biological response. In this study, we investigated the role of alkaline ceramidase 3 (ACER3)/Acer3 and its substrates in immune response. We demonstrated that Acer3 is downregulated, whereas its substrate, C_{18:1}-ceramide, is upregulated in murine immune cells and colonic epithelial cells (CECs) during the innate immune response to LPS. Using Acer3 null mice (Acer3\(^{-/-}\)) and their wild-type (Acer3\(^{+/+}\)) littermates, we further discovered that the inverse regulation of Acer3 and C_{18:1}-ceramide potentiates LPS-induced production of pro-inflammatory cytokines in innate immune cells. More importantly, we found that Acer3 deficiency aggravates dextran sulfate sodium (DSS)-induced colitis and colitis-associated colorectal cancer (CAC) in a murine model. These findings indicate that Acer3/ACER3 and C_{18:1}-ceramide are novel modulators in the innate immune response and that their dysregulation may contribute to the pathogenesis of inflammatory diseases.

## Results

### Acer3 downregulation mediates LPS-induced upregulation of C_{18:1}-ceramide in immune cells and CECs.

The mechanism by which LPS regulates ceramide metabolism is still unclear. Our previous studies have demonstrated that the human ACER3 (ref. 9) and its mouse counterpart Acer3 (ref. 10) regulate unsaturated-long-chain ceramides (ULCCs), including C_{18:1}-Ceramide and C_{20:1}-Ceramide. To investigate if ACER3 mediates the innate immune response, we first determined if ACER3 is regulated by LPS in immune cells by analyzing the NCBI Gene Expression Omnibus (GEO) database. In silico analyses revealed that ACER3 mRNA levels are downregulated in human macrophages,\(^11,12\) monocytes\(^13\) and dendritic cells\(^14\) upon LPS stimulation (Supplementary Figure S1A).

To facilitate our studies on the role of ACER3 in immune response using mouse models, we examined Acer3 expression in response to LPS in murine immune cells. We found that LPS downregulated Acer3 mRNA levels and enzymatic activity in blood mononuclear cells (BMCs) (Figures 1a and d) and PMs (Figures 1b and e) isolated from WT C57BL6/J mice. Certain epithelial cells were shown to have an important role in the innate immune response,\(^15\) including CECs.\(^7\) We found that LPS also downregulated Acer3 mRNA levels (Figure 1c) and its enzymatic activity (Figure 1f) in CECs. Taken together, these results suggest that LPS suppresses ACER3/Acer3 expression in immune cells and CECs.

To determine if Acer3 downregulation had a role in elevating ceramides in response to LPS stimulation, we determined the levels of ceramides in LPS-stimulated BMCs, PMs or CEC isolated from Acer3\(^{-/-}\) mice and their WT littermates (Acer3\(^{+/+}\)). Indeed, liquid chromatography tandem mass spectrometry (LC-MS/MS) analyses found that LPS increased various ceramides in BMCs (Figure 1g and Supplementary Figure S2A), PMs (Figure 1h and Supplementary Figure S2B) or CECs (Figure 1i and Supplementary Figure S2C) and that Acer3 knockout only enhanced the LPS-induced increase of C_{18:1}-ceramide (Figures 1g–i), but not other ceramide species, SPH or sphingosine-1-phosphate (S1P) in these cells (Supplementary Figures S2A and D). These results suggest that Acer3 downregulation is important for LPS-induced increase of C_{18:1}-ceramide in immune cells and CECs.

### Loss of Acer3 or treatment of C_{18:1}-ceramide promotes pro-inflammatory cytokine expression in immune cells and CECs upon LPS stimulation.

Ceramides have been shown to regulate pro-inflammatory cytokines in response to LPS.\(^3,16\) Having demonstrated that Acer3 downregulation mediates LPS-induced elevation of C_{18:1}-ceramide, we investigated if loss of Acer3 affected the expression of pro-inflammatory cytokines in BMCs, PMs and CECs stimulated by LPS. In BMCs, Acer3 deficiency enhanced and prolonged LPS-induced increases in the mRNA levels of II-1β, II-6, II-23a and Tnf-α (Figure 2a). In PMs, Acer3 deficiency enhanced LPS-induced increases in the mRNA levels of II-1β, II-6 and Tnf-α, and to a lesser extent, II-23a (Figure 2b). In CECs, Acer3 deficiency augmented LPS-induced increases in the mRNA levels of II-6, II-23a and Tnf-α but not II-1β (Figure 2c). Acer3 deficiency did not affect the basal mRNA levels of these pro-inflammatory cytokines (Supplementary Figures S3A, S3B, and S3C). These results suggest that Acer3 deficiency potentiates LPS-induced upregulation of pro-inflammatory cytokines in immune cells and CECs.

As Acer3 deficiency potentiated LPS-induced increases of C_{18:1}-ceramide and pro-inflammatory cytokines in cells, we investigated if treatment with C_{18:1}-ceramide mimicked Acer3 deficiency and potentiated LPS-induced pro-inflammatory cytokines in BMCs. Indeed, we found that exogenous C_{18:1}-ceramide but not its saturated analog C_{18:0}-ceramide or C_{16:0}-ceramide significantly enhanced the LPS-induced upregulation of pro-inflammatory cytokines, including II-1β,
Il-23a, Il-6 and Tnf-α (Figure 2d) in BMCs. These results suggest that Acer3 deficiency potentiates LPS-induced expression of pro-inflammatory cytokines in BMCs likely by upregulating C18:1-ceramide.

Acer3 is downregulated, whereas C18:1-ceramide is upregulated in the murine colon tissues during colitis. IBD is manifested by hyperactive immune response in colon. It was shown that this hyperactive immune response is partially attributed to the translocation of microbiomes and/or their products, including LPS, from the colon lumen to mucosa and submucosal layers. As Acer3 and C18:1-ceramide regulated LPS-induced expression of pro-inflammatory cytokines, we investigated whether ACER3/Acer3 and C18:1-ceramide had a role in the pathogenesis of IBD. To this end, we used a murine model of colitis induced by DSS. First, we determined if Acer3 and its regulated C18:1-ceramide were altered in mouse colons in response to DSS-induced colitis. We showed that DSS-induced pathologic manifestations of colitis (Supplementary Figure S4). Upon treatment with DSS, both Acer3 mRNA levels (Figure 3a) and its enzymatic activity (Figure 3b) were significantly decreased in the colon. LC-MS/MS showed that DSS treatment increased various ceramides including C18:1 and C20:1-ceramides in the colon and that Acer3 deficiency enhanced the increase of C18:1-ceramide (Figure 3c), and to a lesser extent, C20:1-ceramide (Figure 3d), but not other ceramide species, SPH or S1P (Supplementary Figures S2E and 2F). These data suggest that Acer3 deficiency...
mainly enhances the colitis-associated elevation of colonic C18:1-ceramide.

Acer3 deficiency enhances upregulation of pro-inflammatory cytokines in colon upon colitis induction. As Acer3 deficiency promoted LPS-induced cytokine upregulation in cells, we determined if Acer3 deficiency also affected inflammatory cytokines in the colon tissues of mice with colitis. The results revealed that Acer3 knockout significantly augmented the colitis-induced increases in the mRNA levels of II-1β, II-6, Tnf-α and II-23α (Figures 4a–d) in colon, although Acer3 deficiency did not affect the basal mRNA levels of these inflammatory cytokines (Supplementary Figure S3D). These results suggest that Acer3 knockout
enhances the expression of pro-inflammatory cytokines in colon upon induction of colitis.

**Acer3 deficiency exaggerates local inflammatory manifestations during acute colitis.** The above results prompted us to investigate whether Acer3 downregulation had a role in pathogenesis of colitis. Colitis characteristics, including bleeding and diarrhea, were monitored in Acer3−/− and Acer3+/+ mice during and after colitis induction. We found that compared with Acer3+/+ mice, Acer3−/− mice had higher colitis activity scores (Figure 5a) with severe diarrhea (Figure 5b) and bleeding (Figure 5c). After DSS withdrawal, Acer3−/− mice recovered from colitis more slowly than Acer3+/+ mice (Figures 5a–c). Correspondingly, Acer3−/− mice also exhibited a greater bodyweight loss (Figure 5d) and higher mortality rates (Figure 5e), although an equal DSS intake was observed between Acer3+/+ and Acer3−/− mice (Supplementary Figure S5). After necropsy, examination of the colon found that during the acute colitis Acer3−/− mice had earlier and greater colonic shortening, compared with Acer3+/+ mice (Figures 5f and g), higher scores of colonic epithelial damage and inflammatory infiltration (Figures 5h and i), and a greater colonic myeloperoxidase (MPO) activity (Figure 5j). Vascular leakage examination by extravasation of Evan’s blue dye (EBD) revealed a significantly greater extravasation of EBD in Acer3−/− mice compared with Acer3+/+ mice (Figures 6a and b). Complete blood cell count (CBC) revealed a greater reduction in red blood cells (RBCs) and hemoglobin in Acer3−/− mice than in Acer3+/+ mice (Figure 6c), suggesting that Acer3 deficiency worsens colonic bleeding during acute colitis. PAS/AB staining showed that upon colitis induction, Acer3−/− mice had a higher loss of mucous-producing epithelial cells, a characteristic lesion of DSS-induced colitis, than Acer3+/+ mice (Figure 6d). Acer3 deficiency did not affect epithelial cell proliferation (Figures 6e–g) but worsened epithelial apoptosis during acute colitis (Figures 6h–j). These results collectively suggest that Acer3 deficiency exaggerates colitis in mice.

**Acer3 deficiency exaggerates systemic inflammatory manifestations during acute colitis.** As systemic inflammatory manifestations, including white blood cell elevation and spleen enlargement, have been observed in acute DSS-induced colitis, we examined Acer3 deficiency in the systemic inflammatory response during colitis. At necropsy, Acer3−/− mice had a greater spleen enlargement (Figures 7a and b) and higher white blood cell counts than Acer3+/+ mice after 7-day DSS treatment (Figure 7c). Acer3 deficiency did not affect circulating immune cell counts at baseline (Figure 7c). These results show that Acer3
deficiency sensitizes mice to colitis-induced systemic inflammation.

**Loss of Acer3 promotes colitis-associated dysplasia progression.** The causal link between colitis and colorectal cancer has been well established. Based on the finding that Acer3 deficiency results in increased colitis in a murine model, we utilized a murine model of colorectal carcinogenesis to examine the role of Acer3 in CAC. Acer3−/− mice were vulnerable to DSS-induced colitis; therefore, we subjected the mice to a single injection of azoxymethane (AOM) followed by a single 7-day course of DSS. In this model, Acer3−/− mice consistently exhibited a higher mortality rate than Acer3+/+ mice (Supplementary Figure S6A). Acer3−/− mice that survived DSS treatment showed more severe colitis, as evidenced by a greater colon shortening (Figure 8a), higher levels of inflammatory cytokines (IL-1β, IL-6, IL-23a and TNF-α) (Figure 8b), higher MPO activity (Figure 8c) and more severe pathological manifestations (Figures 8d and e). We also found that Acer3−/− mice had a greater propensity to develop low-grade dysplasia in the inflamed epithelium (Figures 8f and g) and exhibited a higher tumor incidence (Figure 8h) and greater tumor multiplicity (Figures 8i and j) compared with Acer3+/+ mice. Although Acer3 deficiency did not affect average tumor size (Figure 8k), they harbored large tumors more frequently than Acer3+/+ mice (Figure 8l). Ki-67 staining revealed a higher degree of cell proliferation in the tumors in Acer3−/− mice than in Acer3+/+ mice (Figures 8m and n). Acer3−/− mice also had higher WBC counts and greater splenomegaly than Acer3+/+ mice (Supplementary Figure S6B), suggesting that Acer3 deficiency prolongs systemic inflammatory response in mice during carcinogenesis. Taken together, these data highlight an important role for Acer3 in inhibiting persistent colonic and systemic inflammation and inflammation-associated dysplasia.

**Discussion**

In this study, we demonstrate that Acer3 is an important inflammatory modulator that keeps the innate immune response in check by maintaining the pro-inflammatory bioactive C18:1-ceramide at low levels in immune cells and tissues. LPS has been shown to upregulate ceramide-generating enzymes, including acid SMase, neutral SMase, and SPT in macrophages. However, whether LPS also regulates ceramidases responsible for the catabolism of ceramides in the immune system remains unclear. In silico analyses showed that ACER3 mRNA levels are markedly downregulated in immune cells in response to LPS1−1−1 (Supplementary Figure S1A). Consistent with these data, we found that LPS also markedly downregulated Acer3 in mouse PMs, BMCs and CECs (Figures 1a–f). More importantly, we revealed that Acer3 was downregulated in
Figure 5  Acer3 deficiency exaggerates local and systemic inflammatory manifestations during acute colitis. (a–e) Gender-matched Acer3^{+/+} and Acer3^{-/-} mice at 6 weeks of age were on drinking water containing 2.5% w/v DSS for 7 days. Disease activity (a), diarrhea score (b), rectal bleeding incidence (c), bodyweight loss (d) or survival rate (e) were monitored daily until 3 days after DSS withdrawal (3d Wd), n = 40. (f–j) Mice were killed after 3, 5 or 7-day DSS treatment or 3 days post 7-day DSS treatment (3d Wd), and the colons were removed from the animals. The lengths of the colons were measured (f and g). The colons were rolled, sectioned and stained with H&E (h), and damaged areas were highlighted with red dotted lines. For mice treated with DSS for 3 days, images were captured from the distal colon only. The scores of inflammation (i) and epithelial damage (i) were separately obtained as described in Materials and methods section, and were summed up into total histologic scores (i). Freshly dissected colon tissues were measured for MPO activity (j). Data in (a), (b) and (d) represent mean ± S.E.M., n = 40; data in (j) represent mean ± S.D., n = 5. *P<0.05, **P<0.01, ***P<0.001
colon during acute colitis (Figures 3a and b). During colitis, both immune cells and CECs could be exposed to LPS released from gut microbes\textsuperscript{17,18,20} therefore, colitis-associated downregulation of Acer3 in the colon may be triggered by LPS. Our in vitro findings demonstrated that LPS suppressed Acer3 in both immune cells and CECs, so we postulated that the downregulation of Acer3 in colon may also occur in these cell types during colitis. The mechanism by which LPS downregulates ACER3 or Acer3 is under investigation.

LPS has been shown to increase ceramides by activating either de novo synthesis\textsuperscript{30–33} or sphingomyelin degradation\textsuperscript{3,34–39} However, the role of ceramidases in mediating LPS-induced increase of ceramides in the immune system remains unclear. In this study, we found that LPS elevated various ceramides, including C\textsubscript{18:1}-ceramide, in mouse immune cells and CECs in vitro with a concomitant downregulation of Acer3, and the increase in C\textsubscript{18:1}-ceramide was enhanced by Acer3 knockout (Figures 1g–i, Supplementary Figures S2A and S2C). We also showed that C\textsubscript{18:1}-ceramide was also elevated in colon with a concomitant downregulation of Acer3 during colitis induction in WT mice, and the elevation of C\textsubscript{18:1}-ceramide was augmented by Acer3 deficiency (Figures 3c and d). These findings suggest that LPS increases C\textsubscript{18:1}-ceramide by activating its generation while attenuating its degradation.

Figure 6 Acer3 deficiency exaggerates vascular leakage, mucous depletion and apoptosis in the mouse model of colitis. (a–c) Acer3\textsuperscript{+/+} and Acer3\textsuperscript{−/−} mice were on DSS-containing or regular water for 5 days, and were subjected to vascular permeability assays (a and b) RBC counts and hemoglobin measurements (c). (d) Colonic sections from Acer3\textsuperscript{+/+} and Acer3\textsuperscript{−/−} mice on DSS-containing or regular water for 5 days were co-stained with AB and APS as described under Materials and methods section. (e and f) Colonic sections from Acer3\textsuperscript{+/+} and Acer3\textsuperscript{−/−} mice on DSS-containing or regular water were stained with anti-Ki-67 antibody (e) and Ki-67-positive cells were counted (f) to evaluate proliferation. (g) Colons from Acer3\textsuperscript{+/+} and Acer3\textsuperscript{−/−} mice on DSS-containing or regular water were subjected to western blot analyses with antibody against PCNA or β-actin (a protein loading control), and PCNA level was quantified by densitometry. (h and i) Colonic sections were subjected to TUNEL staining (h) and TUNEL-positive cells were numerated (i). (j) Tissue homogenates prepared as in (g) were subjected to western blot analyses with anti-caspase-3 antibody, and the cleaved caspase-3 was quantified by densitometry. Images in (a), (d), (e) and (h) represent results from one of five pairs of mice. *\textit{P}<0.05, ***\textit{P}<0.001

K Wang et al

Cell Death and Disease
We recently demonstrated that an accumulation of C18:1-ceramide in the central nervous system (CNS) because of Acer3 deficiency led to loss of Purkinje cells, suggesting that C18:1-ceramide may be a pro-death bioactive lipid to certain neurons. However, the role of C18:1-ceramide in non-CNS tissues remains largely unclear. Interestingly, C18:1-ceramide was recently found to be associated with liver fibrosis progression and poor treatment outcome in patients with hepatitis C virus infection, suggesting that C18:1-ceramide may be involved in immune response in humans. This notion is in line with our findings that upregulation of C18:1-ceramide because of Acer3 downregulation potentiates the production of pro-inflammatory cytokines in immune cells and/or tissues. In both in vitro and in vivo systems, we observed that the elevation of C18:1-ceramide was accompanied with the upregulation of cytokines and that treatment with C18:1-ceramide significantly augmented LPS-induced upregulation of inflammatory cytokines (Figure 2d), suggesting a role for C18:1-ceramide in mediating the production of cytokines. Interestingly, we found that C18:1-ceramide did so more potently than its saturated analog, C18:0-ceramide (Figure 2d). Therefore, our studies for the first time demonstrate that C18:1-ceramide is a potent pro-inflammatory bioactive lipid that modulates the innate immune response by regulating inflammatory cytokines in innate immune cells. In contrast to C18:1-ceramide, several studies demonstrated that a non-endogenous, short-chain ceramide, C9-ceramide, inhibits LPS-induced production of cytokines in immune cells. These results suggest that ceramides with different acyl-chains may have distinct roles in regulating immunity. Indeed, increasing studies suggest that ceramides with different acyl-chains, which were once thought to have the same signaling function, have distinct roles in regulating biological responses, including cell proliferation and survival.

How C18:1-ceramide potentiates cytokine expression during innate immune response remains unclear. LPS was shown to induce the translocation of TLR4 and its binding partners to lipid rafts on the plasma membrane and this translocation is thought to be important in activating downstream signaling pathways that mediate cytokine expression. Ceramides with different acyl-chains were shown to affect the properties of lipid rafts distinctly, so they may differentially regulate the translocation of TLR4 to lipid rafts and alter downstream signaling. This may explain why C18:1-ceramide is distinct in potentiating LPS-induced immune response from other tested ceramide species. This possibility is currently under investigations.

Apart from ceramides, SM derived from ceramides are also implicated in LPS-induced inflammation. Our previous study demonstrated that Acer3 knockout caused a slight increase in C18:1-SM levels in mouse tissues, suggesting that part of accumulated C18:1-ceramide is converted to C18:1-SM. In this study, we found that LPS treatment increased C18:1-SM in BMCs and PMs but not CECs and that Acer3 deficiency enhanced the LPS-induced increase of C18:1-SM in PMs and CECs (Supplementary Figures S7A and S7B). Interestingly, Acer3 deficiency did not affect colitis-associated increases in this SM species in the colon (Supplementary Figure S7C). These results suggest that Acer3 deficiency...
Figure 8  Acer3 deficiency promotes colitis-associated dysplasia progression. (a–e) Acer3^{+/+} and Acer3^{-/-} mice were subjected to CAC, and pathological parameters of colitis were examined, including colon lengths (a), mRNA levels of colonic cytokines (Il-1β, Il-6, Il-23a and Tnf-α) (b), MPO activity (c), inflammatory infiltration and epithelial loss (d) and histological scores (e). (f–l) Colons were dissected from Acer3^{+/+} and Acer3^{-/-} mice subjected a mode of CAC. The colons were opened along the mesenteric side and analyzed for colonic dysplasia (f), incidence of colonic dysplasia (g), tumor incidence in colon (h and i), average tumor number (j), average tumor size (k) and tumor size distribution (l), n = 19-20. (m and n) Colon sections were immunostained with anti-Ki67 antibody and imaged (m) and Ki-67-positive cells were enumerated. Data in (b) and (c) represent mean ± S.D., n = 5, *P<0.05, ***P<0.001.
Acer3 suppresses colitis and colorectal cancer
K Wang et al

Materials and Methods
Mice. Mice were housed under conventional laboratory conditions with constant room temperature (22 °C), humidity level (55%), a 12-h light:12-h dark cycle and food (WF Fisher & Son, Somerville, NJ, USA) and water available ad libitum. The Acer3 knockout mouse line was generated as described in our previous studies. Briefly, Acer3 null mice on a Sv129:CS7BL6 mixed genetic background were backcrossed to the CS7BL6/J genetic background for 16 generations. Animal studies were approved by the Institutional Animal Care and Use Committee at Stony Brook University (Stony Brook, NY, USA).

Isolation and culture of murine PMs, BMCs and CECs. PMs were isolated from 8-week-old mice as described. BMCs were isolated from mice at the same age using Ficoll-Paque density centrifugation media (GE Healthcare Life Sciences, Pittsburgh, PA, USA) according to the manufacturer’s instructions. CECs were isolated from mouse colons as described. Briefly, mouse colons were sterilized for 15 min with 0.04% sodium hypochlorite in PBS at room temperature. After being washed with PBS, the colons were incubated for 90 min in PBS containing 3 mM EDTA and 0.05 mM dithiothreitol (DTT) at room temperature. The colons were shaken vigorously in PBS to liberate crypts from the submucosa. The liberated crypts were harvested by centrifugation at 400 rpm for 5 min and were digested for 90 min with 0.25% pancreatin (Sigma-Aldrich, St Louis, MO, USA) at room temperature. CECs released from crypts were collected by centrifugation at 1000 r.p.m. for 5 min, and resuspended in the EDTA/DTT solution. PMs and BMCs were cultured in RPMI 1640 medium containing penicillin, streptomycin and 10% fetal bovine serum in regular culture plates coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). For LPS stimulation, BMCs were plated at a density of 10^6 cells per well in six-well culture plates and were immediately treated with 50 ng/ml LPS from γ-irradiated Escherichia coli 011: B4 (Sigma-Aldrich) or the Veh (PBS). PMs and CECs were plated at the same cell density in regular and Matrigel-coated six-well plates, respectively, for 80 min before being treated with LPS or PBS.

Murine model of colitis. To induce colitis, male and female Acer3+/+ and Acer3−/− mice (approximately 1:1 ratio) at 6 weeks of age were administered on drinking water containing 2.5% w/v DSS (molecular weight, 35 000–50 000; MP Biomedicals, Solon, OH, USA) for up to 7 days. Acer3+/+ or Acer3−/− mice of the same sex were randomly placed in different cages with a maximum of four per cage and were housed in the same animal facility room. Mice in control (CTR) group were administered orally with 200 μl of 0.5% EBD (Sigma-Aldrich) in sterile saline through the lateral tail vein.

Vascular permeability assays. Vascular permeability was examined by EBD extravasation as described with slight modifications. Briefly, after 5-day acute colitis induction, DSS-treated mice or mice on regular water were injected with 150 μl of 0.5% EBD (Sigma-Aldrich) in sterile saline through the lateral tail vein. At 1 h post EBD injection, mice were killed and colons were collected and flushed with PBS. After drying overnight at 56 °C, colons were weighted and the extravasation of EBD was quantified by spectrophotometric absorbance at 610 nm. EBD concentrations were calculated according to a standard curve of known concentrations of EBD and normalized to tissue weights.

Intestinal epithelial permeability assays. Intestinal epithelial permeability was determined by FITC-dextran assays as described with slight modifications. Mice were administered orally with 200 μl of 2 mg/ml FITC-dextran (average molecular weight, 4400; Sigma-Aldrich). Whole blood was collected by cardiac puncture at 6 h after FITC-dextran administration, and serum fluorescent
Complete blood cell count. After killing, whole blood was collected in EDTA-coated tubes from mice by cardiac puncture, and 20 μl of whole blood were used for CBC in Hemavet Hematology Analyzer (Drew Scientific, Waterbury, CT, USA).

Histologic analyses. Mouse colons were transected longitudinally. One half of each colon was rolled onto itself as a ‘Swiss roll’ and fixed in 4% PFA, and another half was snap frozen in liquid nitrogen and stored at −80 °C. Fixed tissues were embedded in paraffin blocks and sectioned. The tissue sections were stained with hematoxylin and eosin (H&E) or periodic acid–Schiff and Alcian blue (PAS/AB). H&E-stained sections were imaged under an Imager M2 microscope (Zeiss, Thornwood, NY, USA), and crypt damage and inflammation were scored as described by Lynn et al.54 using a scoring scheme as presented in Supplementary Table S1. The total histology score is the sum of the subscores of epithelial damage and inflammatory infiltration, thus, the minimal score is 0 and the maximal score is 40. In the CAC model, colon tumor grading was performed by a pathologist on H&E-stained sections in a blinded manner.

Immunohistochemistry. Ki-67 immunostaining was performed as described.55 Ki67-positive cells were scored on 20 × objective field of view under an Imager M2 microscope (Zeiss) in a blinded manner. In the DSS-colitis model, Ki67-positive cells per crypt were calculated; and in the AOM/DSS CAC model, percentage of positive cells in tumors were enumerated.

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays. Colon sections were prepared as described above and subjected to TUNEL assays as described in our previous studies.56 TUNEL-positive cells were enumerated from four random 10 × fields of view in a blinded manner, and positive cells per 10 × field were calculated.

MPO activity assays. MPO activity in mouse colon tissues was determined using MPO Colorimetric Activity Assay Kits (Sigma-Aldrich) according to the manufacturer’s instructions.

Protein concentration determination. Protein concentrations were determined with bovine serum albumin as a standard using a bichinonic acid protein determination kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.

Western blot analyses. Colon tissues were homogenized, and protein extracts were subjected to western blot analyses as described.15 Antibodies used in this study are: proliferating cell nuclear antigen (PCNA) antibody, cleaved caspase-3 antibody, from Cell Signaling, Beverly, MA, USA, and β-actin antibody from Santa Cruz, Dallas, TX, USA. Protein band density was measured by densitometry and protein determination kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.

Alkaline ceramidase activity assays. Colon tissues were homogenized on ice with an electric tissue tearor (Biospec Products, Bartlesville, OK, USA) in buffer A (25 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.25 M sucrose) supplemented with a protease inhibitor mixture (Roche, Indianapolis, IN, USA). After brief sonication, tissue homogenates were centrifuged at 100 000 g for 45 min to sediment all cell membranes, which were resuspended in buffer B (25 mM Tris, pH 7.4, 5 mM CaCl₂ and 150 mM NaCl) and homogenized by sonication. Membrane homogenates (20 μg protein per tissue) were measured for alkaline ceramidase activity using NBD-C6-PC as a substrate as described.15

Liquid chromatography tandem mass spectrometry. Colon tissues were collected and washed with buffer C (25 mM Tris-HCl buffer, pH 7.4, 150 mM NaCl). The colon tissues were homogenized on ice as described earlier in buffer D (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA and 1 mM EGTA). Tissue homogenates (2 mg protein per sample) or intact cells were subjected to lipid extraction and LC-MS/MS analyses for sphingolipids as described.15 Amounts of sphingolipids were normalized to protein concentration.

RNA extraction and quantitative PCR (qPCR). Total RNAs were isolated from fresh tissues or cells using a RNeasy mini kit (QIAGEN, Valencia, CA, USA). RNAs were reversely transcribed into cDNAs and mRNA levels of Acer3, Acer2, Tnf-α, IL-6, II-23a, II-1β and β-actin (as reference gene) were determined by qPCR as described.15 Primers were listed in Supplementary Table S2.

Online data mining. Graphpad Prism 5.0 (La Jolla, CA, USA) was used to analyze ACER3 expression in the NCBI GEO data sets of inflammation-related studies.

Data analysis. Statistical analyses were performed using the Student’s t-test or two-way AVONA using Graphpad Prism 5.0. P-value < 0.05 were considered significant.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We would like to acknowledge the technical support provided by the Research Histology Core Laboratory, Department of Pathology, Stony Brook University. We thank Izolda Mileva in the Lipidomics Core Facility at Stony Brook University for performing sphingolipidomic analyses. We thank Masayuki Wada, Nicolas Coat and Monica Garcia-Barros at Department of Medicine, Stony Brook University for their advices on establishing and examining DSS-colitis and AOM/DSS models. This work was supported, in whole or in part, by National Institutes of Health Grants R01CA104834 and R01CA163825 to CM, P01CA097132 to YAH and CM, and R01CA084197 and R01CA172113 to VWY.
17. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577–594.

18. Gardiner KR, Erwin PJ, Anderson NH, Barr JG, Halliday ML, Rowlands BJ. Colonic bacteria and bacterial translocation in experimental colitis. Br J Surg 1993; 80: 512–516.

19. Gabelle E, Dostert K, Holman C, West R, Scholornerich J, Helferbrand C et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011; 55: 1391–1399.

20. Hudcovic T, Stepanovka R, Cebara J, Tlaskalova-Hogenova H. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in geriatric and conventionally reared immunocompetent and immunodeficient mice. Folia Microbiologica 2001; 46: 569–572.

21. Tolstanova G, Deng X, French SW, Lungo W, Paunovic B, Khomero T et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 2012; 92: 9–21.

22. Akinoto M, Akiada M, Matsui H, Hibi N, Tauchimoto K, Inoue J et al. Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites. Clin Hemorheol Microcirc 2008; 38: 189–199.

23. Kabashima K, Saij T, Murata T, Nagamachi M, Matsuoka T, Segi E et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2007; 117: 1714–1723.

24. Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J 2009; 23: 143–152.

25. Snider AJ, Wu BX, Jenkins RW, Sticca JA, Kawamori T, Hannun YA et al. Loss of neutral ceramide increases inflammation in a mouse model of inflammatory bowel disease. Prostaglandins Other Lipid Mediat 2012; 99: 124–130.

26. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807–1816.

27. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy. J Carcinog 2011; 10: 9.

28. Maciejka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014; 510: 58–67.

29. Sakata A, Yasuda K, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T et al. Inhibition of lipopolysaccharide-induced release of interleukin-8 from intestinal epithelial cells by SMA, a novel inhibitor of sphingomyelinase and its therapeutic effect on dextran sulphate sodium-induced colitis. Cell Immunol 2007; 245: 24–31.

30. Halasiddappa LM, Koefeler H, Futerman AH, Hermetter A. Oxidized phospholipids induce ceramide accumulation in RAW 264.7 macrophages: role of ceramide synthases. PLoS One 2013; 8: e70002.

31. Schiftmann S, Ferreiros N, Brod K, Eberle M, Schreiber Y, Pleischutter W et al. Ceramide synthase 6 plays a critical role in the development of experimental autoimmune encephalomyelitis. J Immunol 2012; 188: 5723–5733.

32. Tong M, Longato L, Ramirez T, Zabala V, Wands JR, de la Monte SM. Acid sphingomyelinase plays a role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J 2009; 23: 143–152.

33. Caretti A, Bragonzi A, Facchini M, De Fino I, Riva C, Gasco P et al. Acid sphingomyelinase expression. Int J Exp Pathol 2014; 95: 49–63.

34. Caretti A, Bragonzi A, Facchini M, De Fino I, Riva C, Gasco P et al. Anti-inflammatory action of lipid nanocarrier-delivered myrcoin: therapeutic potential in cystic fibrosis. Biochim Biophys Acta 2014; 1837: 1208–1216.

35. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. J Cell Physiol 2007; 213: 129–136.

36. Grosch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res 2012; 51: 50–62.

37. Yu VC, Yeh WC, Ohashi PS. LPS/LTR4 signal transduction pathway. Cytkine 2008; 42: 145–151.

38. Triantafillou M, Miyake K, Golenbock DT, Triantafillou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002; 115: 2603–2611.

39. Cremesti AE, Goni FM, Kolesnik R. Role of sphingomyelinase and ceramide in modulating raft:—biophysics properties determine biologic outcome? FEBS Lett 2002; 531: 47–53.

40. Megha, Sawatzki P, Kolter T, Bittman R, London E. Effect of ceramide N-acyl chain and polar headgroup structure on the properties of ordered lipid domains (lipid rafts). Biochim Biophys Acta 2007; 1768: 2205–2212.

41. Halemariam TK, Huan C, Liu J, Li Z, Raman C, Kabielisch M et al. Sphingomyelin synthase 2 deficiency attenuates NKA/PPα2β1 activation. Arterioscler Thromb Vasc Biol 2008; 28: 1519–1526.

42. Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo MS et al. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ Res 2009; 105: 295–303.

43. McCaughan MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 100–113.

44. Gupta S. A decision between life and death during TNF-α-induced signalling. J Clin Immunol 2002; 22: 185–194.

45. Xu R, Jin J, Hu W, Sun W, Bielawski J, Szuic Z et al. Gogi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P. Faseb J 2006; 20: 1813–1825.

46. Sun W, Xu R, Hu W, Jin J, Crellin HA, Bielawski J et al. Uptregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes. J Invest Dermatol 2008; 128: 389–397.

47. Ozaki H, Kawai T, Shuttleworth CW, Won KJ, Suzuki T, Sato K et al. Isolation and characterization of resident macrophages from the smooth muscle layers of murine small intestine. Neurogastroent Motil 2004; 16: 39–51.

48. Whitehead RH, Demmler K, Rockman SP, Watson NK. Cytotoxic growth of epithelial cells from normal colonic mucosa from both mice and humans. Gastroenterology 1999; 117: 825–835.

49. Camerer E, Regard JB, Cornelsen I, Srinivasan Y, Duong DN, Palmer D et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest 2009; 119: 1871–1879.

50. Tolstanova G, Deng X, French SW, Lungo W, Paunovic B, Khomero T et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 2012; 92: 9–21.

51. Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008; 53: 997–1012.

Acer3 suppresses colitis and colorectal cancer
K Wang et al

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)